1. Home
  2. KORE vs CGTX Comparison

KORE vs CGTX Comparison

Compare KORE & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KORE Group Holdings Inc.

KORE

KORE Group Holdings Inc.

HOLD

Current Price

$9.23

Market Cap

89.6M

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

102.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KORE
CGTX
Founded
2003
2007
Country
United States
United States
Employees
539
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.6M
102.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
KORE
CGTX
Price
$9.23
$1.17
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$5.00
$3.33
AVG Volume (30 Days)
71.6K
2.1M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.96
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$0.43
52 Week High
$9.79
$3.83

Technical Indicators

Market Signals
Indicator
KORE
CGTX
Relative Strength Index (RSI) 50.02 47.16
Support Level $9.11 $1.07
Resistance Level N/A $1.23
Average True Range (ATR) 0.09 0.18
MACD -0.00 -0.03
Stochastic Oscillator 18.25 28.92

Price Performance

Historical Comparison
KORE
CGTX

About KORE KORE Group Holdings Inc.

Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: